Psilocybin-assisted CBT for Depression

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2027

Conditions
Major Depressive Disorder
Interventions
DRUG

Psilocybin

Participants will receive two doses of psilocybin (10mg, 25mg).

BEHAVIORAL

Cognitive behavioral therapy

Twelve total sessions of therapy, including manualized cognitive behavioral therapy for major depressive disorder, including psychoeducation about depression, cognitive skills, and behavioral skills as well as preparation for psilocybin.

BEHAVIORAL

Minimal therapeutic support

Six total therapy sessions. Preparation for psilocybin in the first three sessions plus supportive, nondirective psychotherapy in the final three sessions.

Trial Locations (1)

90095

RECRUITING

UCLA Semel Institute, Los Angeles

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

University of California, Los Angeles

OTHER